Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use-Reference-Cited by-同舟云学术

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use

Published:2018-10-11 Issue:15 Volume:132 Page:1573-1583
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Brennan Margs S.¹²^ORCID,Chang Catherine¹,Tai Lin¹,Lessene Guillaume¹²³^ORCID,Strasser Andreas¹²^ORCID,Dewson Grant¹²,Kelly Gemma L.¹²,Herold Marco J.¹²^ORCID

Affiliation:

1. The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; and

2. Department of Medical Biology and

3. Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia

Abstract

Key Points Due to the higher affinity of current MCL-1 inhibitors, huMcl-1 mice have been established. A therapeutic window for S63845 can be established in huMcl-1 mice transplanted with huMcl-1;Eµ-Myc lymphomas.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/15/1573/1407155/blood859405.pdf

Reference36 articles.

1. Cell death signaling;Green;Cold Spring Harb Perspect Biol,2015

2. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

3. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy;Czabotar;Nat Rev Mol Cell Biol,2014

4. Mitochondria-judges and executioners of cell death sentences;Bhola;Mol Cell,2016

5. The landscape of somatic copy-number alteration across human cancers;Beroukhim;Nature,2010

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors;Journal of Medicinal Chemistry;2024-08-05

2. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia;Cell Death & Disease;2024-06-12

3. Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma;EJC Paediatric Oncology;2024-06

4. BCL-2 inhibition in haematological malignancies: Clinical application and complications;Blood Reviews;2024-05

5. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death;Cell Death & Differentiation;2024-03-27